Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.55 |
| ▸ | FLT3 | P36888 | 6/20 | 0.48 |
| ▸ | FLT4 | P35916 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394231 | 0.96 | FLT3 (0.50) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL396850 | 0.92 | NTRK1 (0.53) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL397947 | 0.92 | NTRK1 (0.58) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL394110 | 0.89 | FLT3 (0.48) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL394525 | 0.89 | FLT3 (0.51) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL393780 | 0.88 | NTRK1 (0.52) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL399058 | 0.87 | FLT3 (0.48) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL398246 | 0.86 | NTRK1 (0.53) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL398243 | 0.86 | TLK2 (0.48) | NTRK1FLT3FLT4KDRKIT | |
| SCHEMBL394537 | 0.86 | NTRK1 (0.52) | NTRK1FLT3FLT4KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |